Preclinical studies have demonstrated IDE275's (GSK959) potential as a best-in-class WRN inhibitor, inducing single-agent tumor regressions in MSI-H patient-derived xenograft (PDX) and cell line ...

ZW171, a mesothelin (MSLN)-targeting T cell engager, currently in global Phase 1 clinical studies, shows promising preclinical activity in an expanded range of MSLN-positive tumor models including ...

Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215000, China ...

A novel, allosteric and highly potent USP1 inhibitor, LAE120 exhibits robust tumor inhibitory activity across various xenograft models Significantly accelerated the progress of drug discovery ...